trending Market Intelligence /marketintelligence/en/news-insights/trending/3rxrtan_azolgy3skuz8-a2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

EyePoint Pharmaceuticals elects new board chairman

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


EyePoint Pharmaceuticals elects new board chairman

EyePoint Pharmaceuticals Inc., a specialty biopharmaceutical company, elected Göran Ando to be the chairman of the company's board.

Ando was appointed to the board in June 2018, according to a Sept. 10 press release. He previously held positions with Pfizer Inc., held several senior appointments at GlaxoSmithKline PLC, and most recently served as the CEO for Celltech Group Ltd.

As part of the transition, David Mazzo will step down as the non-executive chairman but will remain on the board.